ʻO Kepakemapa 1 ka hoʻomaka ʻana o ka mahina lymphoma a mai kēia lā ua hoʻohui ʻia he 2 mau lāʻau hou i ka PBS no nā maʻi lymphoma.
Ua hoʻolaha koke ke Kuhina Ola Ola ʻo Greg Hunt mai ka lā 1 o Kepakemapa, e loaʻa i nā poʻe maʻi Australia me ka relapsed / refractory primary mediastinal B cell lymphoma (PMBCL) a me ka relapsed / refractory Chronic Lymphocytic Leukemia (CLL) a me Small Lymphocytic lymphoma (SLL) e loaʻa hou. nā koho lapaʻau i loaʻa iā lākou ma ka PBS.
He ʻano liʻiliʻi loa ka PMBCL o ka lymphoma a hiki i nā mea maʻi ke komo i kēia manawa keytruda inā ua hoʻi hou lākou i nā lāʻau ma mua a i ʻole lākou i hōʻole i ka mālama ʻana. ʻO KEYTRUDA (Pembrolizumab) kahi lāʻau immunotherapy e hiki ai i ke kino ponoʻī ke pale aku i ka lymphoma.
Heluhelu (Acalabrutinib) e loaʻa pū ma ka PBS no nā poʻe maʻi maʻi Australia me Chronic Lymphocytic Leukemia a me Small Lymphocytic Lymphoma. Manaʻo ʻia kēia mau subtypes lymphoma he maʻi maʻi maʻi maʻi no ka mea ʻaʻole ia e hele akā hāʻawi ʻo Calquence i nā poʻe maʻi kūpono me kahi koho lapaʻau hou.
Mahalo nui ʻo Lymphoma Australia i nā poʻe maʻi a me nā lālā ʻē aʻe o ke kaiāulu i kōkua iā mākou ma ka waiho ʻana i ka PBAC no laila ua ʻae ʻia kēia mau lāʻau lapaʻau hou no nā poʻe maʻi kūpono.
No ka ʻike hou aku a me ka manaʻo pāpaho, e kelepona iā Lymphoma Australia CEO Sharon Winton ma 0431 483 204.
